Stocks and Investing
Stocks and Investing
Fri, August 16, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Colin Bristow Maintained (ALXO) at Strong Buy with Decreased Target to $4 on, Aug 16th, 2024
Colin Bristow of UBS, Maintained "ALX Oncology Holdings Inc." (ALXO) at Strong Buy with Decreased Target from $25 to $4 on, Aug 16th, 2024.
Colin has made no other calls on ALXO in the last 4 months.
There are 3 other peers that have a rating on ALXO. Out of the 3 peers that are also analyzing ALXO, 1 agrees with Colin's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Bradley Canino of "Stifel" Reiterated at Hold with Decreased Target to $3 on, Friday, August 9th, 2024
These are the ratings of the 2 analyists that currently disagree with Colin
- Swayampakula Ramakanth of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $25 on, Tuesday, August 13th, 2024
- Li Watsek of "Cantor Fitzgerald" Reiterated at Buy on, Monday, August 12th, 2024
Contributing Sources